NEW YORK, July 18 - Lynx Therapeutics reported second-quarter revenues of $4.4 million Wednesday, up 57 percent from the same period last year, and separately said BASF-LYNX, a joint venture with German chemical giant BASF, had agreed to license its Megaclone micro-bead DNA detection technology.

Lynx attributed the increase in revenue primarily to technology access fees that Lynx's customers paid for Megaclone technology. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.